
## Mass drug administration for falciparum malaria



A practical field manual






## Mass drug administration for falciparum malaria







A practical field manual





Mass drug administration for falciparum malaria: a practical field manual

ISBN 978-92-4-151310-4 (electronic version) ISBN 978-92-4-000773-4 (print version)

## © World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo)

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Mass drug administration for falciparum malaria: a practical field manual. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and aueries on rights and licensing, see http://www.who.int/about/licensing.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shal WHO be liable for damages arising from its use.

## **Contents**

Acknowledgements Abbreviations and acronyms		
1. 1	INTRODUCTION	
1.1	Background	1
1.2	Definitions	1
1.3	Objective	1
1.4	WHO recommendations	2
2.	ORGANIZATION AND IMPLEMENTATION	
2.1	Design phase (macroplanning)	3
	2.1.1 Identify agencies to support the ministry of health	3
	2.1.2 Establish a task force or coordinating committee	4
	2.1.3 Conduct a context analysis	6
	2.1.4 Determine the target population and geographical areas	7
	2.1.5 Choose the antimalarial medicine	10
	2.1.6 Estimate the requirement for antimalarial medicine, and order it	13
	2.1.7 Determine the delivery strategy	13
	2.1.8 Determine the period of intervention	14
	2.1.9 Determine the number of rounds	15
	2.1.10 Establish a chronogram	17
	2.1.11 Draw up a budget	17
2.2	Planning and preparation	18
	2.2.1 Micro-planning	18
	2.2.2 Logistics	20
	2.2.3 Human resources	22
	2.2.4 Community engagement, social mobilization and communication	26
2.3	Implementation	32
	2.3.1 Stock management	32
	2.3.2 Distribution of antimalarial medicine	34
	2.3.3 Supervision	37
	2.3.4 Data collection	30

2.3.5 Coordination	42
2.3.6 Treatment of malaria cases after mass drug administration	43
3. MONITORING AND EVALUATION	44
3.1 Monitoring system	44
3.2 Estimate of coverage	44
3.2.1 Distribution coverage	44
3.2.2 Post-MDA campaign survey	46
3.3 Monitoring consumption	46
3.4 Pharmacovigilance	47
3.4.1 Definitions	48
3.4.2 Safety communication	49
3.4.3 Surveillance of adverse drug reactions	49
3.5 Monitoring drug resistance	50
3.6 Evaluating impact	51
4. REPORTING  5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA	53 55
	55
5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA	
5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA REFERENCES	55 56
5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA  REFERENCES  ANNEXES	55 56 59
5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA  REFERENCES  ANNEXES  Annex 1 - Standard distribution of populations in a developing country  Annex 2 - Available artemisinin-based combination therapy:	<b>55 56 59</b>
5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA  REFERENCES  ANNEXES  Annex 1 - Standard distribution of populations in a developing country  Annex 2 - Available artemisinin-based combination therapy: dosing, formulation and presentation	<b>55 56 59 60</b>
5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA  REFERENCES  ANNEXES  Annex 1 - Standard distribution of populations in a developing country  Annex 2 - Available artemisinin-based combination therapy: dosing, formulation and presentation  Annex 3 - Example of calculation of orders for antimalarial medicine  Annex 4 - Example of a chronogram for mass drug administration for malaria	<b>55 56 59 60 66</b>
5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA  REFERENCES  ANNEXES  Annex 1 - Standard distribution of populations in a developing country  Annex 2 - Available artemisinin-based combination therapy: dosing, formulation and presentation  Annex 3 - Example of calculation of orders for antimalarial medicine  Annex 4 - Example of a chronogram for mass drug administration for malaria (distribution at 8 weeks)	<b>55 56 59 60 66 69</b>
5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA  REFERENCES  ANNEXES  Annex 1 - Standard distribution of populations in a developing country  Annex 2 - Available artemisinin-based combination therapy: dosing, formulation and presentation  Annex 3 - Example of calculation of orders for antimalarial medicine  Annex 4 - Example of a chronogram for mass drug administration for malaria (distribution at 8 weeks)  Annex 5 - Example of micro-planning in urban Western Area, Sierra Leone	<b>55 56 59 60 66 69 72</b>

Annex 9 - Household visit for MDA, step by step			
<b>Annex 10 -</b> Algorithm to assist community health workers in applying exclusion criteria	79		
<b>Annex 11 -</b> Algorithm for determining the pregnancy status of women of reproductive age (15–49 years) (based on and adapted from algorithms used in malaria MDA in Mozambique by the Centro de Investigação em Saúde de Manhiça)	80		
<b>Annex 12 -</b> Example of laminated leaflet used by community health workers in Sierra Leone in 2014–2015 to explain treatment dosage	81		
<b>Annex 13 -</b> Example of tally sheet (adapted from that used in Sierra Leone in 2014–2015)	82		
<b>Annex 14 -</b> Example of a household registration form (adapted from the Zambia MDA programme delivery handbook)	83		
Annex 15 - Example of supervisors' checklist used in Sierra Leone in 2014-2015	84		
Annex 16 - Example of MDA Card	85		
<b>Annex 17 -</b> Example of daily summary sheet to be completed by distribution tear supervisors (adapted from that used in Sierra Leone in 2014–2015)	n 86		
<b>Annex 18 -</b> Example of database for data compilation (used in Sierra Leone in 2014–2015)	87		
<b>Annex 19 -</b> Example of standard template for reporting a suspected adverse drug reaction	89		
Annex 20 - Example of questionnaire for post-MDA survey	92		
<b>Annex 21 -</b> Example of pharmacovigilance preparedness checklist (used in Sierra Leone in 2014–2015)	96		
Annex 22 - Example of an MDA pharmacovigilance training module	97		



https://www.yunbaogao.cn/report/index/report?reportId=5\_26246

